• Th. Dorval


Foley (1953) was the first to demonstrate that the immune system is capable of rejecting tumours. He showed that immunisation of mice against tumour cells prevented the uptake of lethal doses of tumour cells. This experiment opened the way for studies on immunotherapy for cancer in humans.


Bone Metastasis Objective Response Rate Renal Cell Cancer Prospective Randomise Trial Active Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Borden EC (1984) Progress towards therapeutic application of interferons. Cancer 54: 2770–2776.PubMedCrossRefGoogle Scholar
  2. Coley WB (1982) The treatment of malignant tumors by repeated inoculations of erysipelas, with a report of original cases. Am J Med Sci 105: 487–511.CrossRefGoogle Scholar
  3. Drebin JA, Link VC, Stern DF et al (1995) Down regulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 695–706.CrossRefGoogle Scholar
  4. Falkson C, Falkson G, Falkson H (1991) Improved results with the addition of interferon alfa-2a to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1408.PubMedGoogle Scholar
  5. Foley EJ (1953) Antigenic properties of methylcholenthrene-induced tumours in mice of the strain of origin. Cancer Res 13: 835–883.PubMedGoogle Scholar
  6. Hersh EM, Taylor CW (1991) Immunotherapy by active immunization. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biological therapy of cancer. JB Lippincott, Philadelphia, pp 613–626.Google Scholar
  7. Hoover HC Jr, Hanna MG Jr (1991) Immunotherapy by active immunization. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biological therapy of cancer. JB Lippincott, Philadelphia, pp 670–681.Google Scholar
  8. Legha S (1989) Current therapy for malignant melanoma. Semin Oncol 16: 34–44.PubMedGoogle Scholar
  9. Muss HB (1991) The use of interferon in renal cell carcinoma. Eur J Cancer 27 (suppl 4): 84–87.Google Scholar
  10. Richards JM, Mehta M, Ramming K et al (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1343.PubMedGoogle Scholar
  11. Rosenberg SA, Lotze MT, Muul ML et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 15: 889–897.CrossRefGoogle Scholar
  12. Traversari C, Van Der Bruggen P, Luesher IF et al (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigene MZ2-E. J Exp Med 176 (5): 1453–1457.PubMedCrossRefGoogle Scholar
  13. West WH, Tauer KW, Yannelli JR et al (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 15: 898–906.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • Th. Dorval

There are no affiliations available

Personalised recommendations